Stereotaxis, a company specializing in surgical robotics for minimally invasive endovascular intervention, has received CE mark approval for its MAGiC ablation catheter.

The MAGiC catheter is a robotically-navigated magnetic ablation catheter to perform cardiac ablation procedures that treat arrhythmia. It was developed based on insights gathered over almost 20 years and 150,000 robotic ablation procedures that used predecessor catheters.

Its uniquely placed magnets and design of its distal section supports intuitive navigation, consistent contact forces, and enhanced stability, according to Stereotaxis. MAGiC is available with iConnect and the eContact module, which provides catheter tissue contact info as well as clear electrogram and responsive temperature data.

Tip cooling is accomplished with low-flow irrigation that reduces overall fluid load on patients, and protects against char and coagulation.

The MAGiC catheter was approved in Europe for delivery of local lesions in cardiac tissue for the treatment of arrhythmias. Clinical experience with MAGiC in an ongoing clinical study in Europe supports expectations for broad adoption of MAGiC across robotic users, the company said.

“We are thrilled to announce this significant milestone and introduce the MAGiC catheter to European physicians and patients,” said David Fischel, Stereotaxis chairman and CEO. “We want to thank and recognize the significant contributions from clinicians who guided us throughout the development efforts and team members of Stereotaxis and Osypka that made this possible. We look forward to seeing MAGiC serve as one of the key pillars in our effort to make robotics broadly impactful and beneficial in electrophysiology and endovascular surgery.”

In November 2024, the company’s Genesis surgical robot received regulatory approval from China’s National Medical Products Administration (NMPA).